Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05704829
Title NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer (ADAPTHER2-IV)
Acronym ADAPTHER2-IV
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors West German Study Group
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU


No variant requirements are available.